COMPANY

Inomagen Therapeutics

Keywords: From press sources:atrial fibrillation

Profile checked Oct 10, 2026

NIH awards 4

Annual award amounts. Total $5.3M.

Aug 28, 2026 NIH award 1R44HL187127-01 FY2026: $1,412,149 awarded for that fiscal year; activity R44 (SBIR); PI MOEN, ROBERT CHARLES; recipient as written: INOMAGEN THERAPEUTICS, INC, CHICAGO, IL. A New and Disruptive Gene Based source ↗
Jun 23, 2023 NIH award 5R44HL154912-03 FY2023: $1,749,913 awarded for that fiscal year; activity R44 (SBIR); PI MOEN, ROBERT CHARLES; recipient as written: INOMAGEN THERAPEUTICS, INC, CHICAGO, IL. A New and Disruptive Gene Based source ↗
Feb 4, 2022 NIH award 4R44HL154912-02 FY2022: $1,636,504 awarded for that fiscal year; activity R44 (SBIR); PI MOEN, ROBERT CHARLES; recipient as written: INOMAGEN THERAPEUTICS, INC, CHICAGO, IL. A New and Disruptive Gene Based source ↗
Apr 2, 2021 NIH award 1R44HL154912-01A1 FY2021: $462,689 awarded for that fiscal year; activity R44 (SBIR); PI MOEN, ROBERT CHARLES; recipient as written: INOMAGEN THERAPEUTICS, INC, CHICAGO, IL. A New and Disruptive Gene Based source ↗

NIH award NIH awarded $1.41M (SBIR Phase II 1R44HL187127-01, new, notice Aug 28, 2026). NIH RePORTER 1R44HL187127-01 (Aug 28, 2026)
Evidence (1 event)
- Aug 28, 2026 · NIH RePORTER 1R44HL187127-01
  Organization: INOMAGEN THERAPEUTICS, INC; City/State: CHICAGO, IL; Project number: 1R44HL187127-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1412149; Administering IC: National Heart Lung and Blood Institute; Project title: A New and Disruptive Gene Based Therapy for Atrial Fibrillation; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals